Compare SHLS & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHLS | NBTX |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2020 | 2018 |
| Metric | SHLS | NBTX |
|---|---|---|
| Price | $10.12 | $39.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 1 |
| Target Price | $9.07 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 5.8M | 81.3K |
| Earning Date | 05-05-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.86 | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $475,331,000.00 | N/A |
| Revenue This Year | $26.24 | $58.17 |
| Revenue Next Year | $11.52 | N/A |
| P/E Ratio | $41.63 | ★ N/A |
| Revenue Growth | ★ 19.07 | N/A |
| 52 Week Low | $4.44 | $4.93 |
| 52 Week High | $13.18 | $57.14 |
| Indicator | SHLS | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.44 | 54.43 |
| Support Level | $8.10 | $38.89 |
| Resistance Level | $11.27 | $41.89 |
| Average True Range (ATR) | 0.82 | 2.41 |
| MACD | -0.03 | 0.51 |
| Stochastic Oscillator | 53.95 | 62.65 |
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.